Axsome Therapeutics (NASDAQ:AXSM) Insider Ari Maizel Sells 7,500 Shares of Stock

Axsome Therapeutics, Inc. (NASDAQ:AXSM) insider Ari Maizel sold 7,500 shares of Axsome Therapeutics stock in a transaction on Wednesday, January 21st. The stock was sold at an average price of $184.44, for a total transaction of $1,383,300.00. The sale was disclosed in a document filed with the SEC, which is available at this link.

Axsome Therapeutics Stock Performance

NASDAQ AXSM opened at $185.96 on Friday. The company has a debt-to-equity ratio of 1.66, a current ratio of 1.57 and a quick ratio of 1.50. Axsome Therapeutics, Inc. has a 1 year low of $86.99 and a 1 year high of $191.50. The company has a market capitalization of $9.37 billion, a PE ratio of -39.82, a P/E/G ratio of 9.86 and a beta of 0.44. The company has a fifty day moving average of $159.39 and a two-hundred day moving average of $133.10.

Axsome Therapeutics (NASDAQ:AXSM) last posted its earnings results on Monday, November 3rd. The company reported ($0.94) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.12). Axsome Therapeutics had a negative return on equity of 277.31% and a negative net margin of 40.90%.The firm had revenue of $170.99 million for the quarter, compared to analyst estimates of $162.96 million. The company’s quarterly revenue was up 63.2% compared to the same quarter last year. As a group, analysts expect that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Axsome Therapeutics News Summary

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: Piper Sandler is bullish ahead of a likely Auvelity label expansion by April 30, which would expand the approved uses for Axsome’s depression drug and could materially increase addressable market and sales expectations. Piper Sandler Bullish on Axsome Therapeutics (AXSM) Ahead of Likely Auvelity Label Expansion by April 30
• Positive Sentiment: HC Wainwright has increased some earnings estimates and reiterated a Buy rating with a $260 target, signaling conviction in Axsome’s medium-term revenue trajectory and valuation upside. This analyst support is likely propping up investor sentiment despite volatility. HC Wainwright Brokers Increase Earnings Estimates for AXSM
• Positive Sentiment: Related coverage from HC Wainwright and other outlets highlights expectations for strong price appreciation and has coincided with recent share strength, providing momentum that could support further gains if clinical and label catalysts materialize. HC Wainwright Forecasts Strong Price Appreciation for Axsome Therapeutics (NASDAQ:AXSM) Stock
• Positive Sentiment: Axsome recently hit a new 12‑month high following analyst upgrades, reflecting elevated optimism from the sell side which can attract momentum and institutional interest. Axsome Therapeutics (NASDAQ:AXSM) Hits New 12-Month High Following Analyst Upgrade
• Neutral Sentiment: Analyst roundup pieces summarize diverse views from ~14 analysts; consensus leans positive but shows dispersion in price targets and timing, indicating investor outcomes depend heavily on upcoming regulatory/label and sales data. 3AXSM : Expert Outlook: Axsome Therapeutics Through The Eyes Of 14 Analysts
• Negative Sentiment: HC Wainwright’s detailed model changes are mixed — while they raised several quarterly and FY2025 estimates and the target, they also trimmed forecasts for certain quarters (notably Q2 and Q3 adjustments). That mix introduces near-term earnings uncertainty that can create volatility until clinical/label outcomes and actual sales datapoints arrive.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Needham & Company LLC reissued a “buy” rating and issued a $225.00 price objective on shares of Axsome Therapeutics in a report on Monday, January 5th. B. Riley initiated coverage on shares of Axsome Therapeutics in a research report on Wednesday, October 1st. They issued a “buy” rating and a $179.00 price target for the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Axsome Therapeutics in a research report on Wednesday, January 14th. TD Cowen restated a “buy” rating on shares of Axsome Therapeutics in a research note on Wednesday, December 31st. Finally, Piper Sandler upped their target price on shares of Axsome Therapeutics from $148.00 to $223.00 and gave the company an “overweight” rating in a report on Friday, January 16th. Nineteen analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Axsome Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $203.17.

Hedge Funds Weigh In On Axsome Therapeutics

Several institutional investors have recently bought and sold shares of AXSM. Stanley Laman Group Ltd. purchased a new position in Axsome Therapeutics during the third quarter worth about $2,125,000. Swiss National Bank increased its position in Axsome Therapeutics by 6.9% during the 2nd quarter. Swiss National Bank now owns 65,200 shares of the company’s stock worth $6,806,000 after purchasing an additional 4,200 shares during the period. Bank of New York Mellon Corp increased its position in Axsome Therapeutics by 55.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 203,632 shares of the company’s stock worth $21,257,000 after purchasing an additional 72,609 shares during the period. Assenagon Asset Management S.A. raised its stake in shares of Axsome Therapeutics by 62.9% during the 3rd quarter. Assenagon Asset Management S.A. now owns 294,771 shares of the company’s stock worth $35,800,000 after buying an additional 113,811 shares in the last quarter. Finally, Los Angeles Capital Management LLC raised its stake in shares of Axsome Therapeutics by 154.5% during the 2nd quarter. Los Angeles Capital Management LLC now owns 4,424 shares of the company’s stock worth $462,000 after buying an additional 2,686 shares in the last quarter. 81.49% of the stock is owned by institutional investors and hedge funds.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.